bacterial polysaccharide immune globulin

a human hyperimmune globulin for treatment/prevention of Haemophilus influenzae type b & pneumococcal disease; contains 10-60 times higher concentrations of antibody compared to HIB vaccine

Also Known As:

Networked: 9 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pelton, S I: 1 article (12/2000)

Related Diseases

1.	Body Weight (Weight, Body) 10/08/1987 - "To evaluate the efficacy of passive immunization with a human hyperimmune globulin (bacterial polysaccharide immune globulin [BPIG]) prepared from the plasma of immunized adult donors, we randomly assigned 703 infants in a double-blind fashion to receive 0.5 ml of BPIG per kilogram of body weight (n = 353) or 0.5 ml of saline (n = 350) intramuscularly at 2, 6, and 10 months of age. " 02/01/1993 - "Antibody responses to measles vaccine were inhibited for up to 5 months after a BPIG dose of 80 mg IgG per kilogram of body weight, but responses to rubella vaccine were inhibited for only 2 months. "
2.	Pneumococcal Infections 12/08/2000 - "Insight into potential changes can be obtained from reviewing middle ear and nasopharyngeal isolates from studies of antimicrobial prophylaxis and bacterial polysaccharide immune globulin for prevention of OM and PCV for prevention of invasive pneumococcal disease, respectively. " 06/01/1992 - "Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease." 10/08/1987 - "During the fourth month, one case of Hib meningitis and two cases of pneumococcal bacteremia developed in the BPIG group, whereas there were no Hib or pneumococcal infections in the placebo group. " 10/08/1987 - "During the first 90 days after BPIG or placebo injection, no Hib or pneumococcal infections were detected in the BPIG group, whereas seven Hib infections (six cases of bacteremia and one of meningitis) and four pneumococcal infections (bacteremia) were detected in the placebo group (P = 0.007 and 0.06, respectively). "
3.	Haemophilus Infections 01/01/1993 - "BPIg has been demonstrated to prevent Hib infections when it is administered to infants at 4-month intervals. " 06/01/1992 - "In high-risk Apache infants, BPIG given at 2, 6, and 10 months of age provided significant protection from invasive Hib infection during infancy. " 06/01/1992 - "Thus, BPIG may have utility in the prevention of Hib infections in high-risk patients who cannot be immunized adequately with Hib conjugate vaccines." 10/08/1987 - "During the first 90 days after BPIG or placebo injection, no Hib or pneumococcal infections were detected in the BPIG group, whereas seven Hib infections (six cases of bacteremia and one of meningitis) and four pneumococcal infections (bacteremia) were detected in the placebo group (P = 0.007 and 0.06, respectively). " 05/01/1994 - "In July, 1989, Alaska Area Native Health Service initiated a passive immunization project in the YKD using bacterial polysaccharide immunoglobulin (BPIG) administered at 3-month intervals to prevent Hib infections in infants less than 13 months of age. "
4.	Infections 10/08/1987 - "Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin." 04/01/1988 - "BPIG may be of value in preventing human bacterial infection and may also inhibit development of antibody if it affects local infection or colonization. " 04/01/1988 - "At levels of anticapsular immunoglobulin G similar to those of human adults, BPIG given systemically prevented pneumococcal OM and disseminated infection in chinchillas. " 07/01/1984 - "As a first step in exploring the feasibility of passive antibody prophylaxis and therapy of serious infections caused by common encapsulated bacteria, we have immunized healthy adults with Haemophilus influenzae type b vaccine, 14-valent pneumococcal vaccine, and meningococcal group A and C vaccine; collected plasma by repeated pheresis; and purified a hyperimmune globulin termed bacterial polysaccharide immune globulin by the cold-ethanol fractionation method of Cohn and Oncley. "
5.	Bacteremia 04/01/1988 - "Bacteremia developed in 6 of 12 saline- and 0 of 12 BPIG-treated animals (P = 0.007). " 10/08/1987 - "During the fourth month, one case of Hib meningitis and two cases of pneumococcal bacteremia developed in the BPIG group, whereas there were no Hib or pneumococcal infections in the placebo group. " 10/08/1987 - "During the first 90 days after BPIG or placebo injection, no Hib or pneumococcal infections were detected in the BPIG group, whereas seven Hib infections (six cases of bacteremia and one of meningitis) and four pneumococcal infections (bacteremia) were detected in the placebo group (P = 0.007 and 0.06, respectively). "

Related Drugs and Biologics

1.	bacterial polysaccharide immune globulin
2.	Globulins
3.	Immunoglobulins (Immunoglobulin)
4.	Vaccines
5.	Polysaccharides (Glycans)
6.	Immunoglobulin G (IgG)
7.	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)
8.	Conjugate Vaccines
9.	Rubella Vaccine
10.	Oligosaccharides

Related Therapies and Procedures

1.	Therapeutics
2.	Blood Component Removal (Apheresis)